Northwest Biotherapeutics Shares Outstanding 2006-2021 | NWBO

Northwest Biotherapeutics shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Northwest Biotherapeutics Annual Shares Outstanding
(Millions of Shares)
2020 725
2019 564
2018 440
2017 243
2016 111
2015 78
2014 59
2013 33
2012 12
2011 6
2010 4
2009 3
2008 3
2007 2
2006 0
2005 0
Northwest Biotherapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-09-30 1,136
2021-06-30 1,159
2021-03-31 835
2020-12-31 725
2020-09-30 748
2020-06-30 698
2020-03-31 649
2019-12-31 564
2019-09-30 577
2019-06-30 597
2019-03-31 529
2018-12-31 440
2018-09-30 516
2018-06-30 425
2018-03-31 356
2017-12-31 243
2017-09-30 281
2017-06-30 208
2017-03-31 161
2016-12-31 111
2016-09-30 115
2016-06-30 104
2016-03-31 98
2015-12-31 78
2015-09-30 90
2015-06-30 76
2015-03-31 69
2014-12-31 59
2014-09-30 61
2014-06-30 57
2014-03-31 52
2013-12-31 33
2013-09-30 35
2013-06-30 29
2013-03-31 27
2012-12-31 12
2012-09-30 11
2012-06-30 162
2012-03-31 10
2011-12-31 6
2011-09-30 8
2011-06-30 5
2011-03-31 5
2010-12-31 4
2010-09-30 4
2010-06-30 4
2010-03-31 4
2009-12-31 3
2009-09-30 3
2009-06-30 3
2009-03-31 3
2008-12-31 3
2008-09-30 3
2008-06-30 3
2008-03-31 3
2007-12-31 2
2007-09-30 3
2007-06-30 1
2007-03-31 0
2006-12-31 0
2006-09-30 0
2006-06-30 1
2006-03-31 0
2005-12-31 0
2005-09-30 0
2005-06-30 0
2005-03-31 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.882B $0.001B
Northwest Biotherapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing immunotherapy products that safely generate and enhance immune system responses to treat cancer.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75